JP2017535258A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535258A5
JP2017535258A5 JP2017519646A JP2017519646A JP2017535258A5 JP 2017535258 A5 JP2017535258 A5 JP 2017535258A5 JP 2017519646 A JP2017519646 A JP 2017519646A JP 2017519646 A JP2017519646 A JP 2017519646A JP 2017535258 A5 JP2017535258 A5 JP 2017535258A5
Authority
JP
Japan
Prior art keywords
site
exogenous
goi
nucleic acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017519646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535258A (ja
JP6668340B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/056653 external-priority patent/WO2016064999A1/en
Publication of JP2017535258A publication Critical patent/JP2017535258A/ja
Publication of JP2017535258A5 publication Critical patent/JP2017535258A5/ja
Application granted granted Critical
Publication of JP6668340B2 publication Critical patent/JP6668340B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017519646A 2014-10-23 2015-10-21 新規cho組込み部位およびその使用 Active JP6668340B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067774P 2014-10-23 2014-10-23
US62/067,774 2014-10-23
PCT/US2015/056653 WO2016064999A1 (en) 2014-10-23 2015-10-21 Novel cho integration sites and uses thereof

Publications (3)

Publication Number Publication Date
JP2017535258A JP2017535258A (ja) 2017-11-30
JP2017535258A5 true JP2017535258A5 (enExample) 2018-11-22
JP6668340B2 JP6668340B2 (ja) 2020-03-18

Family

ID=54602002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519646A Active JP6668340B2 (ja) 2014-10-23 2015-10-21 新規cho組込み部位およびその使用

Country Status (16)

Country Link
US (5) US9816110B2 (enExample)
EP (1) EP3209785B1 (enExample)
JP (1) JP6668340B2 (enExample)
KR (1) KR102243243B1 (enExample)
CN (1) CN107109434B (enExample)
AR (1) AR102420A1 (enExample)
AU (1) AU2015335921B2 (enExample)
BR (1) BR112017008022A2 (enExample)
CA (1) CA2965495C (enExample)
EA (1) EA037255B1 (enExample)
IL (1) IL251674B (enExample)
MX (1) MX2017005306A (enExample)
MY (1) MY184103A (enExample)
SG (1) SG11201703149RA (enExample)
TW (2) TWI747808B (enExample)
WO (1) WO2016064999A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209785B1 (en) 2014-10-23 2019-07-31 Regeneron Pharmaceuticals, Inc. Novel cho integration sites and uses thereof
US10329594B1 (en) 2015-09-03 2019-06-25 CHO Plus, Inc. Cell lines for high level production of protein-based pharmaceuticals
US11649449B2 (en) 2015-09-03 2023-05-16 CHO Plus, Inc. Hybrid cell lines for high level production of a target protein
BR112018071283A2 (pt) 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
US11530277B2 (en) * 2016-04-20 2022-12-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP2020501593A (ja) * 2016-12-20 2020-01-23 ディベロップメント センター フォー バイオテクノロジーDevelopment Center For Biotechnology 改変細胞、調製方法、及び構築物
WO2018148196A1 (en) * 2017-02-07 2018-08-16 Sigma-Aldrich Co. Llc Stable targeted integration
WO2018150271A1 (en) * 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
US11959093B2 (en) 2017-03-19 2024-04-16 Applied Stemcell, Inc. Integration sites and uses thereof
KR102531749B1 (ko) * 2017-08-11 2023-05-10 베링거 인겔하임 인터내셔날 게엠베하 Cho 세포 내 통합 부위
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
WO2019126562A1 (en) * 2017-12-22 2019-06-27 Bio-Rad Laboratories, Inc. Controlling phenotype of organisms with crispr/cas gene targeting
IL275462B2 (en) * 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
CN109295092B (zh) * 2018-10-30 2021-06-29 江南大学 一种cho细胞基因组内nw_003613638-1稳定表达蛋白质的应用
CN109136193B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006884764-1稳定表达蛋白质的应用
CN109337927B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006880285-1稳定表达蛋白质的应用
CN109295093B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006882456-1稳定表达蛋白质的应用
CN109321604B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006882077-1稳定表达蛋白质的应用
CN109207432B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006883358-1稳定表达蛋白质的应用
EP3980544A1 (en) * 2018-12-21 2022-04-13 F. Hoffmann-La Roche AG Targeted integration of nucleic acids
SG11202110076PA (en) * 2019-04-02 2021-10-28 Chugai Pharmaceutical Co Ltd Method of introducing target-specific foreign gene
EP3990649A1 (en) 2019-06-26 2022-05-04 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
EP3901266A1 (en) * 2020-04-22 2021-10-27 LEK Pharmaceuticals d.d. Super-enhancers for recombinant gene expression in cho cells
JP7887833B2 (ja) * 2020-06-02 2026-07-10 キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー 遺伝子挿入用の複数のドックを有している細胞株
KR20230027043A (ko) * 2020-06-24 2023-02-27 제넨테크, 인크. 핵산의 표적화 통합
WO2022079083A1 (en) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Nucleic acid constructs for va rna transcription
CN113755447B (zh) * 2021-09-23 2022-04-29 云舟生物科技(广州)股份有限公司 一种用于生产腺病毒的293a细胞株及其制备与应用
CN118159660A (zh) 2021-10-18 2024-06-07 瑞泽恩制药公司 多核苷酸的受控转录
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
US20250098652A1 (en) * 2022-01-28 2025-03-27 The Trustees Of Columbia University In The City Of New York Genetic Modifications for Xenotransplantation
CN117305334B (zh) * 2022-06-21 2024-11-08 深圳太力生物技术有限责任公司 靶向整合细胞及其制备方法、生产目标基因表达产物的方法
US20240168018A1 (en) 2022-11-18 2024-05-23 Regeneron Pharmaceuticals, Inc. Methods for detecting and evaluating viruses and virus-like particles
CN118726475B (zh) * 2023-03-28 2025-07-08 深圳太力生物技术有限责任公司 核酸、重组载体、靶向整合细胞、基因表达方法和应用
WO2024211287A1 (en) * 2023-04-03 2024-10-10 Seagen Inc. Production cell lines with targeted integration sites
CN121794393A (zh) 2023-09-07 2026-04-03 里珍纳龙药品有限公司 经共价表面修饰的腺相关病毒的生产和纯化
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus
WO2026050618A1 (en) 2024-08-29 2026-03-05 Regeneron Pharmaceuticals, Inc. Polynucleotide constructs and cell lines for recombinant aav production
WO2026162509A1 (en) 2025-01-28 2026-08-06 Selexis Sa Integration regions and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
ES2375266T3 (es) 1998-07-21 2012-02-28 Millipore Corporation Un polinucleótido que comprende un elemento de apertura de cromatina ubicuo (ucoe).
US6521419B1 (en) * 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
AU2002254529A1 (en) 2001-04-04 2002-10-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Nucleic acids for transgene expression
US20040045043A1 (en) * 2002-05-20 2004-03-04 Finney Robert E. Compositions and methods for generating conditional knockouts
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
DK2150617T3 (en) * 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
EP3156494B8 (en) * 2008-12-04 2018-09-19 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
CA2832095A1 (en) 2011-04-05 2012-10-11 The Scripps Research Institute Chromosomal landing pads and related uses
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP3683319A1 (en) * 2011-06-01 2020-07-22 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
US9222105B2 (en) * 2011-10-27 2015-12-29 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
CA2871524C (en) 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
EP3209785B1 (en) 2014-10-23 2019-07-31 Regeneron Pharmaceuticals, Inc. Novel cho integration sites and uses thereof

Similar Documents

Publication Publication Date Title
JP7546015B2 (ja) 発現強化座位の使用に基づく抗体を作製するための組成物および方法
JP7831937B2 (ja) ゲノム組込みのための方法および組成物
Massarwa et al. WIP/WASp-based actin-polymerization machinery is essential for myoblast fusion in Drosophila
Nozaki et al. BBS1 is involved in retrograde trafficking of ciliary GPCRs in the context of the BBSome complex
ES2716735T3 (es) Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado
CN109195986B (zh) 基于使用表达增强性基因座来制备抗体的组合物和方法
JP2019514358A5 (enExample)
CN107090463A (zh) 编码新型疱疹抗原的核酸分子、包含所述核酸分子的疫苗及其使用方法
JP2018502583A5 (enExample)
JP2017535258A (ja) 新規cho組込み部位およびその使用
JP2016539629A5 (enExample)
JP2017514501A5 (enExample)
KR20010024296A (ko) 벡터 구조체와 세포 dna의 비상동 재조합법에 의한내생 유전자 발현
JP2011504721A5 (enExample)
JP6817944B2 (ja) 最適化治療用分子を製造する方法
EP2121917A2 (fr) Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
JP2023532665A5 (enExample)
Rosenfeld et al. A primer set for comprehensive amplification of V-genes from rhesus macaque origin based on repertoire sequencing
CN112469732A (zh) 使用胰岛素样生长因子1-加密脱氧核糖核酸构建体及肝细胞生长因子-加密脱氧核糖核酸构建体的神经病变治疗
WO2008100424A2 (en) Animals and cells with genomic target sites for transposase-mediated transgenesis
CN106995821B (zh) Jurkat-KI-R5细胞系及其构建方法和应用
JP2016540506A5 (enExample)
CN106086070B (zh) 一种ProtoRAG转座子系统及其用途
EP3775230A1 (en) Compositions and methods for the treatment of stargardt disease
CN109295082B (zh) 肿瘤特异性基因表达盒、重组表达载体及构建方法和应用